PMID: 11335042May 4, 2001Paper

Increased density of glutamate/N-methyl-D-aspartate receptors in superior temporal cortex in schizophrenia

Neuroscience Letters
S Nudmamud, G P Reynolds

Abstract

Saturable radioligand binding of [(3)H]L-689,560 to the glycine site of the N-methyl-D-aspartate (NMDA) receptor was determined bilaterally in superior temporal cortex (BA22) and prefrontal cortex (BA10) taken post mortem from patients with schizophrenia and matched control subjects. A significant increase in NMDA receptor density above control values was found bilaterally in BA22 in schizophrenia, but not in BA10. The effect was greatest in those patients described as primarily type II, in whom the effect was significantly lateralized, with a greater elevation in the left hemisphere. A significant decrease in NMDA receptor density was found in rat frontal cortex following chronic antipsychotic drug administration, indicating that prior drug treatment was unlikely to have contributed to the differences in schizophrenia.

References

Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Jun 1, 1989·Journal of Neurochemistry·J F DeakinA J Cross
Jan 1, 1985·Schizophrenia Bulletin·T J Crow
Dec 1, 1995·Archives of General Psychiatry·J W Olney, N B Farber
Jan 28, 1998·Critical Reviews in Neurobiology·C A Tamminga
Feb 14, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·G D Pearlson

❮ Previous
Next ❯

Citations

Feb 1, 2003·Pharmacology & Therapeutics·Christine Konradi, Stephan Heckers
Nov 27, 2002·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Kenji HamaseKiyoshi Zaitsu
Oct 17, 2012·Molecular Psychiatry·C S WeickertT W Weickert
May 12, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Elizabeth ScarrBrian Dean
May 1, 2002·Clinical Neuropharmacology·Joëlle MicallefOlivier Blin
May 1, 2008·BMC Genomics·Nikola A BowdenPaul A Tooney
May 2, 2009·BMC Psychiatry·Daniel Martins-de-SouzaEmmanuel Dias-Neto
Sep 25, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Bo LiEffat S Emamian
Feb 4, 2016·Acta Biochimica Et Biophysica Sinica·Peijun Ju, Donghong Cui
May 12, 2009·Neurochemistry International·Joanna M Wierońska, Andrzej Pilc
Jan 20, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Teresa Marie du BoisXu-Feng Huang
Aug 18, 2004·Biological Psychiatry·Michael K HarteGavin P Reynolds
Jul 25, 2013·Neuroscience Letters·Rachanee ChanasongSutisa Nudmamud-Thanoi
May 28, 2015·The Australian and New Zealand Journal of Psychiatry·Brian DeanRobert E McCullumsmith
Jul 12, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Teresa M du BoisXu-Feng Huang
Jul 26, 2005·Journal of Neuroscience Research·Chao Deng, Xu-Feng Huang
Nov 27, 2020·Epigenomics·Camila Marcelino LoureiroGavin P Reynolds

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here